https://www.selleckchem.com/products/ABT-869.html
Purpose To describe the efficacy and safety of botulinum toxin A (Botox) in patients with benign essential blepharospasm. Methods Retrospective review of operation, injection, and medical records. Results Information of 29 patients (nine males) was reviewed, and the average age of benign essential blepharospasm onset was 59.1 years. The average number of injections per patient was 14.2 ± 8.2 (5-44) and the average follow-up was 75.8 ± 47.3 months (15-18. The average unit dose was 14.2 ± 8.2 (10-3 ipsilaterally in the patient's first
Like
Comment
Share
